Anti-Mouse TIGIT [Clone 1G9] — Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse TIGIT [Clone 1G9] — Purified in vivo PLATINUM™ Functional Grade
Product No.: T736
Clone 1G9 Target TIGIT Formats AvailableView All Product Type Hybridoma Monoclonal Antibody
Alternate Names Vstm3, VSIG9 Isotype Mouse IgG1 κ Applications ELISA , FA , FC |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Recombinant murine TIGIT tetramers. Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? ELISA, FA, FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 1G9 activity is directed against mouse TIGIT.
Background TIGIT is an immunoreceptor that inhibits multiple immune cell responses, including T cell
priming by dendritic cells, tumor cell killing by NK cells and cytotoxic T cells, and also
enhances the immune suppressive activity of regulatory T cells1. TIGIT is a novel member of the Ig-superfamily distantly related to Nectins and Necls that aligns with the distal Ig-V-type domains of Nectin1-4, poliovirus receptor (PVR; CD155), DNAM-1 (CD226), and TACTILE (CD96)2. TIGIT is an attractive target for cancer therapy due to its role as an immune checkpoint1,3. Immunotherapy targeting TIGIT and the PD-1/PD-L1 pathway is capable of tumor suppression. 1G9 was generated by immunizing TIGIT-/- mice with recombinant mouse TIGIT tetramers3. Draining lymph nodes were collected and fused with Sp2/0-Ag14. Supernatants were screened for specific binding by anti-TIGIT ELISA and flow cytometry. Hybridomas that showed TIGIT-specific binding were expanded and subcloned and single colonies sorted by flow cytometry. Comparative immunofluorescence staining of activated primary TIGIT-expressing wildtype T cells and TIGIT-/- T cells was performed to confirm specificity. 1G9 was found to fully block TIGIT binding to CD155, a high-affinity TIGIT ligand. However, 1G9 does not deplete TIGIT+ cells in vivo under steady-state conditions. Additionally, 1G9 does not affect T cell proliferation in vitro. 1G9 has agonistic anti-TIGIT activity in vivo, leading to a reduction in T cell expansion and pro-inflammatory cytokine production, and is also able to reduce experimental autoimmune encephalomyelitis (EAE) severity in mice. Antigen Distribution TIGIT is expressed on NK cells, activated T cells, memory T cells, and a subset of regulatory T cells. Ligand/Receptor CD155 (PVR) and CD112 (PVRL2) NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. In Vivo Applications of Clone 1G9 in MiceClone 1G9 is a mouse monoclonal antibody (IgG1, κ) that specifically recognizes mouse TIGIT (T cell immunoreceptor with Ig and ITIM domains). Its in vivo use is primarily as an agonistic antibody to modulate immune responses mediated by TIGIT, an inhibitory immune checkpoint receptor expressed on T cells, including regulatory T cells (Tregs) and subsets of activated and memory T cells. Key In Vivo Applications
Experimental Impact
Summary Table
ConclusionClone 1G9 is principally employed in mice to agonize TIGIT signaling in vivo, thereby suppressing T cell-driven inflammation and modulating immune checkpoint activity without depleting TIGIT+ cells. This makes it a critical reagent for investigating the immunoregulatory functions of TIGIT in autoimmune, inflammatory, and tolerance models. Clone 1G9 is most commonly used as an anti-mouse TIGIT monoclonal antibody, targeting the immunoregulatory protein TIGIT on T and NK cells. In the literature, several other antibodies or proteins are frequently used alongside 1G9, largely because TIGIT biology is intimately connected to related checkpoint proteins and their ligands in immunological research, particularly cancer and autoimmunity studies. The most commonly used antibodies/proteins with 1G9 include:
Summary Table: Common Antibodies/Proteins Used with 1G9
Additional context:
According to reagent suppliers and published reviews on TIGIT biology, these combinations are standard in the literature using the 1G9 clone antibody. Key Findings of Clone 1G9 Anti-TIGIT Antibody in Scientific LiteratureAgonistic Activity and T Cell Modulation
Functional Specificity and Mechanism
Contrast with Other Clones
Summary Table of Key Effects
ConclusionClone 1G9 is a well-characterized, agonistic anti-mouse TIGIT monoclonal antibody that modulates immune responses by suppressing T cell activation and cytokine production in vivo, without depleting TIGIT-expressing cells. Its therapeutic potential is highlighted by reduced severity in autoimmune models, making it a valuable tool for studying TIGIT biology and for exploring immunotherapeutic strategies targeting this checkpoint. Dosing regimens of the anti-mouse TIGIT antibody clone 1G9 vary depending on the mouse model and experimental context, with doses typically ranging from 200 μg to 400 μg per mouse, and the schedule tailored to disease kinetics and study aims.
Key points:
No data in the provided sources indicate lower threshold doses (e.g., 5 μg) for 1G9; the lowest and most common effective doses reported are in the 200–400 μg range. If your application or disease model differs—for example, in oncology or infection—dosing regimens might need further adjustment, usually within the published range and based on factors such as disease kinetics, antibody half-life, and the readout of interest. References & Citations1 Harjunpää H, Guillerey C. Clin Exp Immunol. 200(2):108-119. 2020. 2 Boles KS, Vermi W, Facchetti F, et al. Eur J Immunol. 39(3):695-703. 2009. 3 Dixon KO, Schorer M, Nevin J, et al. J Immunol. 200(8):3000-3007. 2018. 4 Chen Y, Huang H, Li Y, et al. Front Immunol. 13:832230. 2022. 5 Zhou XM, Li WQ, Wu YH, et al. Front Immunol. 9:2821. 2018. 6 Wu L, Mao L, Liu JF, et al. Cancer Immunol Res. 7(10):1700-1713. 2019. 7 Peng H, Li L, Zuo C, et al. Front Immunol. 13:1039226. 2022. 8 Stirm K, Leary P, Wüst D, et al. J Immunother Cancer. 11(2):e006263. 2023. 9 Schorer M, Rakebrandt N, Lambert K, et al. Nat Commun. 11(1):1288. 2020. 10 Freed-Pastor WA, Lambert LJ, Ely ZA, et al. Cancer Cell. 39(10):1342-1360.e14. 2021. 11 Ozmadenci D, Shankara Narayanan JS, et al. Proc Natl Acad Sci U S A. 119(17):e2117065119. 2022. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
T737 | |
T738 | |
T735 | |
T741 | |
T742 | |
T736 |
